Equity Overview
Price & Market Data
Price: $2.40
Daily Change: -$0.15 / 6.25%
Range: $2.40 - $3.00
Market Cap: $2,479,799
Volume: 136,001
Performance Metrics
1 Week: -0.80%
1 Month: -11.43%
3 Months: -24.39%
6 Months: -23.57%
1 Year: -31.49%
YTD: -25.86%
Company Details
Employees: 31
Sector: Health technology
Industry: Pharmaceuticals: other
Country: Israel
Details
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Gottingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications, such as plaque psoriasis, psoriatic arthritis, asthma, and wet macular degeneration. It also develops PC111, a monoclonal antibody in development for treating Pemphigus, Steven Johnson's Syndrome and Toxic Epidermal Necrolysis. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.